44 / 82
302
53.- Ruckwardt T J, Morabito K M, Graham
B S. Determinants of early immune responses to RSV
infection. Curr Opin Virol 2016; 16: 151-6.
54.- Mahony J, Chong S, Merante F, Yaghou-
bian S, Sinha T, Lisle C, et al. Development of
a respiratory virus panel test for detection of twenty
respiratory viruses by use of multiplex PCR and a fluid
microbead based assay. J Clin Microbiol 2007; 45:
2965-70.
55.- Jeong J, Kim K, Jeong S, Park J, Lee S, Seo Y.
Comparison of sputum and nasopharyngeal swabs for
detection of respiratory viruses. J Med Virol 2014; 86:
2122-7.
56.- Panel Respiratorio Film Array. http://www.
biomerieuxchile.cl/diagnostico-clinico/productos/biomerieux-worldwide.
57.- Simoes EA, DeVincenzo J P, Boeckh M, Bont
L, Crowe J E Jr, Griffiths P, et al Challenges and
opportunities in developing respiratory syncytial virus
therapeutics. J Infect Dis 2015; 211 Suppl 1:S1-S20.
doi: 10.1093/infdis/jiu828.
58.- Girardi B, Astudillo P, Zúñiga F. El programa
IRA en Chile: hitos e historia. Rev Chil Pediatr 2001;
72: 292-300.
59.- Mochizuki H, Kusuda S, Okada K, Yoshi-
hara S, Furuya H, Simões EA. Palivizumab Pro-
phylaxis in Preterm Infants and Subsequent Recurrent
Wheezing: 6 Year Follow Up Study A J Respir Crit Care
Med 2017; 196: 29-38.
60.- American Academy of Pediatrics. Clini-
cal Practice Guidelines: The Diagnosis, Management
and Prevention of Bronchiolitis. Pediatrics 2014; 134:
e1474-e502.
61.- Anderson L J, Dormitzer PR, Nokes D J,
Rappuoli R, Roca A, Graham B S. Strategic
priorities for respiratory syncytial virus (RSV) vaccine
development. Vaccine 2013; 31 Suppl 2: B209-15.
62.- Kim H W, Canchola J G, Brandt C G, Pyles
G, Channock R M, Jensen K, et al. Respiratory
syncytial virus disease in infants despite prior adminis-
tration of antigenic inactivated vaccine. Am J Epidemiol
1969; 89: 422-34.
63.- Path Organization.
http://www.path.org/vacci-neresources/details.php?i=1562
http://www.path.org/publications/files/CVIA_rsv_snapshot_final.pdf
64.- Rey-Jurado E, Kalergis A M. Immunological
features of Respiratory Syncytial Virus-caused Pneumo-
nia. Implications for vaccine design. Int J Mol Sci 2017,
18,556; doi10.3390/ ijms18030556.
65.- Rey-Jurado E, Soto J, Gálvez N, KalergisA
M. A safe and efficient BCG vectored vaccine to prevent
the disease caused by the human Respiratory Syncytial
Virus. Human Vaccines & Immunotherapeutics 2017,
doi 10.1080 /21645515.
66.- Glenn G M, Fries L F, Thomas D N, Smith G,
Kpamegan H, Lu H, Flyer D, et al ARandomized,
Blinded, Controlled, Dose-Ranging Study of a Respira-
tory Syncytial Virus Recombinant Fusion (F) Nanopar-
ticle Vaccine in Healthy Women of Child bearing Age.
J Infect Dis 2016; 213: 411-42.
Correspondencia a:
Dra. Patricia Díaz A.
Programa de Fisiopatología, ICBM.
Facultad de Medicina, Universidad de Chile.
Avda. Salvador 486. Providencia, Santiago,Chile
Email:
patriciadiazamor@gmail.comP. V. Díaz A. et al.
Rev Chil Enferm Respir 2017; 33: 293-302